Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Review

Cancer risk in immune-mediated inflammatory diseases (IMID)

Authors: Rudi Beyaert, Laurent Beaugerie, Gert Van Assche, Lieve Brochez, Jean-Christophe Renauld, Manuelle Viguier, Veronique Cocquyt, Guy Jerusalem, Jean-Pascal Machiels, Hans Prenen, Pierre Masson, Edouard Louis, Filip De Keyser

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic inflammation - has protumorigenic effects, but inflammatory cells also mediate an immune response against the tumor and immunosuppression is known to increase the risk for certain tumors.
This article reviews current literature on the role of inflammation in cancer and the cancer risk in immune-mediated inflammatory diseases (IMIDs). We discuss the effect on cancer risk of different drug classes used in the treatment of IMIDs treatment, including biologicals such as tumor necrosis factor (TNF) inhibitors.
Overall cancer incidence and mortality risk are similar to the general population in inflammatory bowel disease (IBD), and slightly increased for rheumatoid arthritis and psoriasis, with risk profiles differing for different tumor types. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF treatment in psoriasis. Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a history of cancer are scarce.
This review provides clinicians with a solid background to help them in making decisions about treatment of immune-mediated diseases in patients with a tumor history.
This article is related to another review article in Molecular Cancer: http://​www.​molecular-cancer.​com/​content/​12/​1/​86.
Literature
1.
Williams JP, Meyers JA: Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care. 2002, 8 (21 Suppl): S664-S681. quiz S682–5PubMed
2.
3.
4.
Solinas G, Germano G, Mantovani A, Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009, 86: 1065-1073.PubMedCrossRef
5.
Burnet FM: Immunological surveillance in neoplasia. Transplant Rev. 1971, 7: 3-25.PubMed
6.
Bui JD, Schreiber RD: Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Curr Opin Immunol. 2007, 19: 203-208.PubMedCrossRef
7.
Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol. 2004, 22: 329-360.PubMedCrossRef
8.
Nakachi K, Hayashi T, Imai K, Kusunoki Y: Perspectives on cancer immuno-epidemiology. Cancer Sci. 2004, 95: 921-929.PubMedCrossRef
9.
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001, 410: 1107-1111.PubMedCrossRef
10.
Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI: Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000, 191: 661-668.PubMedCentralPubMedCrossRef
11.
Street SEA, Trapani JA, MacGregor D, Smyth MJ: Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon. J Exp Med. 2002, 196: 129-134.PubMedCentralPubMedCrossRef
12.
Engel AM, Svane IM, Rygaard J, Werdelin O: MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol. 1997, 45: 463-470.PubMedCrossRef
13.
Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, Werdelin O: Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol. 1996, 26: 1844-1850.PubMedCrossRef
14.
Müller-Hermelink N, Braumüller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Förster I, Huss R, Weber WA, Kneilling M, Röcken M: TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell. 2008, 13: 507-518.PubMedCrossRef
15.
Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454: 436-444.PubMedCrossRef
16.
17.
Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005, 5: 749-759.PubMedCrossRef
18.
Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JFF, Wilson M, Mehta Z, Meade TW: Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012, 379: 1602-1612.PubMedCrossRef
19.
Jacobs EJ, Newton CC, Gapstur SM, Thun MJ: Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst. 2012, 104: 1208-1217.PubMedCrossRef
20.
Baron JA: Aspirin and cancer: trials and observational studies. J Natl Cancer Inst. 2012, 104: 1199-1200.PubMedCrossRef
21.
Pasche B: Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA. 2013, 309: 2598-2599.PubMedCrossRef
22.
23.
Zumsteg A, Christofori G: Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr Opin Oncol. 2009, 21: 60-70.PubMedCrossRef
24.
25.
26.
Ben-Neriah Y, Karin M: Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 2011, 12: 715-723.PubMedCrossRef
27.
Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997, 336: 1066-1071.PubMedCrossRef
28.
29.
Karin M, Cao Y, Greten FR, Li Z-W: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2: 301-310.PubMedCrossRef
30.
Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005, 64: 1414-1420.PubMedCentralPubMedCrossRef
31.
Zhang J, Wu P, Hu Y: Clinical and marketed proteasome inhibitors for cancer treatment. Curr Med Chem. 2013, 20: 2537-2551.PubMedCrossRef
32.
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005, 64: 1421-1426.PubMedCentralPubMedCrossRef
33.
Smitten AL, Simon TA, Hochberg MC, Suissa S: A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008, 10: R45-PubMedCentralPubMedCrossRef
34.
Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, Klareskog L: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006, 54: 692-701.PubMedCrossRef
35.
Loftus EV: Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004, 126: 1504-1517.PubMedCrossRef
36.
Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR: Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010, 95: 1216-1220.PubMedCentralPubMedCrossRef
37.
Watanabe T, Soga K, Hirono H, Hasegawa K, Shibasaki K, Kawai H, Aoyagi Y: Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World J Gastroenterol. 2009, 15: 231-239.PubMedCentralPubMedCrossRef
38.
Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C: Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci. 2011, 56: 578-585.PubMedCrossRef
39.
Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Jewell D: Cancer in patients with ulcerative colitis, Crohn’s disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol. 2008, 20: 297-304.PubMedCrossRef
40.
Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM: Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer. 2011, 117: 1163-1171.PubMedCentralPubMedCrossRef
41.
Silano M, Volta U, Mecchia AM, Dessì M, Di-Benedetto R, De-Vincenzi M: Delayed diagnosis of coeliac disease increases cancer risk. BMC Gastroenterol. 2007, 7: 8-PubMedCentralPubMedCrossRef
42.
Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T: Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010, 105: 1480-1487.PubMedCrossRef
43.
Laukoetter MG, Mennigen R, Hannig CM, Osada N, Rijcken E, Vowinkel T, Krieglstein CF, Senninger N, Anthoni C, Bruewer M: Intestinal cancer risk in Crohn’s disease: a meta-analysis. J Gastrointest Surg. 2011, 15: 576-583.PubMedCrossRef
44.
Canavan C, Abrams KR, Mayberry J: Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006, 23: 1097-1104.PubMedCrossRef
45.
Hemminki K, Li X, Sundquist J, Sundquist K: Cancer risks in Crohn disease patients. Ann Oncol. 2009, 20: 574-580.PubMedCrossRef
46.
Szekanecz Z, Szekanecz E, Bakó G, Shoenfeld Y: Malignancies in autoimmune rheumatic diseases - a mini-review. Gerontology. 2011, 57: 3-10.PubMedCrossRef
47.
Prizment AE, Alonso A, Folsom AR, Ahmed RL, Virnig BA, Warshaw EM, Anderson KE: Association between psoriasis and incident cancer: the Iowa’s Women’s Health Study. Cancer Causes Control. 2011, 22: 1003-1010.PubMedCentralPubMedCrossRef
48.
Hannuksela-Svahn A, Pukkala E, Läärä E, Poikolainen K, Karvonen J: Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol. 2000, 114: 587-590.PubMedCrossRef
49.
Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL: The risk of malignancy associated with psoriasis. Arch Dermatol. 2001, 137: 778-783.PubMed
50.
Chen Y-J, Wu C-Y, Chen T-J, Shen J-L, Chu S-Y, Wang C-B, Chang Y-T: The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol. 2011, 65: 84-91.PubMedCrossRef
51.
52.
Boffetta P, Gridley G, Lindelöf B: Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol. 2001, 117: 1531-1537.PubMedCrossRef
53.
Ji J, Shu X, Sundquist K, Sundquist J, Hemminki K: Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer. 2009, 100: 1499-1502.PubMedCentralPubMedCrossRef
54.
Söderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M: Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case–control study in Sweden. Eur J Cancer. 2006, 42: 3028-3033.PubMedCrossRef
55.
Gelfand JM, Berlin J, Van-Voorhees A, Margolis DJ: Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol. 2003, 139: 1425-1429.PubMedCrossRef
56.
Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard M, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le-Maître M, Ortonne J-P, Paul C: Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013, 27 (Suppl 3): 36-46.PubMedCrossRef
57.
Richard M, Barnetche T, Horreau C, Brenaut E, Pouplard C, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le-Maître M, Misery L, Ortonne J-P, Paul C: Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol. 2013, 27 (Suppl 3): 2-11.PubMedCrossRef
58.
Askling J, Brandt L, Lapidus A, Karlén P, Björkholm M, Löfberg R, Ekbom A: Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005, 54: 617-622.PubMedCentralPubMedCrossRef
59.
Boffetta P, Rabkin CS, Gridley G: A cohort study of cancer among sarcoidosis patients. Int J Cancer. 2009, 124: 2697-2700.PubMedCrossRef
60.
Liu H, Ding Q, Yang K, Zhang T, Li G, Wu G: Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia. Rheumatology (Oxford). 2011, 50: 343-348. 10.1093/rheumatology/keq304.CrossRef
61.
Chen Y-J, Chang Y-T, Wang C-B, Wu C-Y: Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med. 2010, 123: 1150-1156.PubMedCrossRef
62.
Kiss E, Kovacs L, Szodoray P: Malignancies in systemic lupus erythematosus. Autoimmun Rev. 2010, 9: 195-199.PubMedCrossRef
63.
Rosenthal AK, McLaughlin JK, Gridley G, Nyrén O: Incidence of cancer among patients with systemic sclerosis. Cancer. 1995, 76: 910-914.PubMedCrossRef
64.
Magruder JT, Elahi D, Andersen DK: Diabetes and pancreatic cancer: chicken or egg?. Pancreas. 2011, 40: 339-351.PubMedCrossRef
65.
Stevens RJ, Roddam AW, Beral V: Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer. 2007, 96: 507-509.PubMedCentralPubMedCrossRef
66.
Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002, 56: 48-54.PubMedCrossRef
67.
Veloso FT: Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome?. World J Gastroenterol. 2011, 17: 2702-2707.PubMedCentralPubMed
68.
Bernstein CN, Blanchard JF, Kliewer E, Wajda A: Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001, 91: 854-862.PubMedCrossRef
69.
Thomas T, Abrams KA, Robinson RJ, Mayberry JF: Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007, 25: 657-668.PubMedCrossRef
70.
Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A: Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004, 53: 1813-1816.PubMedCentralPubMedCrossRef
71.
Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T: Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007, 133: 1099-1105. quiz 1340–1PubMedCentralPubMedCrossRef
72.
73.
El-Gabalawy H, Guenther LC, Bernstein CN: Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010, 85 (Imid): 2-10.PubMedCrossRef
74.
Naldi L: Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol. 2010, 28: 88-92.PubMedCrossRef
75.
Patel RV, Clark LN, Lebwohl M, Weinberg JM: Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009, 60: 1001-1017.PubMedCrossRef
76.
Stern RS: Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol. 2006, 142: 1132-1135.PubMed
77.
Väkevä L, Reitamo S, Pukkala E, Sarna S, Ranki A: Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Derm Venereol. 2008, 88: 117-120.PubMedCrossRef
78.
Lee H-M, Sugino H, Nishimoto N: Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol. 2010, 2010: 676284-PubMedCentralPubMed
79.
Smith PP, Gordon C: Systemic lupus erythematosus: clinical presentations. Autoimmun Rev. 2010, 10: 43-45.PubMedCrossRef
80.
Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE: Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer. 2011, 104: 1478-1481.PubMedCentralPubMedCrossRef
81.
82.
Martinez OM, De-Gruijl FR: Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant. 2008, 8: 2205-2211.PubMedCrossRef
83.
84.
Burnet FM: Implications of immunological surveillance for cancer therapy. Isr J Med Sci. 1971, 7: 9-16.PubMed
85.
Karran P, Attard N: Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2008, 8: 24-36.PubMedCrossRef
86.
Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009, 374: 1617-1625.PubMedCrossRef
87.
Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD: Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010, 8: 268-274.PubMedCentralPubMedCrossRef
88.
Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005, 54: 1121-5.PubMedCentralPubMedCrossRef
89.
Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R: Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol. 2012, 27: 385-389.PubMedCrossRef
90.
Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume J-C, Lamarque V, Dubertret L: Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003, 120: 211-216.PubMedCrossRef
91.
Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H: Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007, 41: 21-28.PubMedCrossRef
92.
Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S, Harkness A, Lewis D, Littlejohn G, Miller MH, Ryan PFJ, Jolley D: Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008, 59: 794-799.PubMedCrossRef
93.
Salliot C, van der-Heijde D: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009, 68: 1100-1104.PubMedCentralPubMedCrossRef
94.
Krathen MS, Gottlieb AB, Mease PJ: Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol. 2010, 37: 2205-2215.PubMedCrossRef
95.
Brodsky RA: High dose cyclophosphamide treatment for autoimmune disorders. Sci World J. 2002, 2: 1808-15.CrossRef
96.
Vlaovic P, Jewett MAS: Cyclophosphamide-induced bladder cancer. Can J Urol. 1999, 6: 745-748.PubMed
97.
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975, 72: 3666-3670.PubMedCentralPubMedCrossRef
98.
Fiers W, Beyaert R, Brouckaert P, Everaerdt B, Haegeman C, Suffys P, Tavernier J, Vanhaesebroeck B: TNF: its potential as an antitumour agent. Dev Biol Stand. 1988, 69: 143-151.PubMed
99.
Van-Horssen R, Ten-Hagen TLM, Eggermont AMM: TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006, 11: 397-408.PubMedCrossRef
100.
101.
Cantaert T, Baeten D, Tak PP, Van-Baarsen LGM: Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther. 2010, 12: 219-PubMedCentralPubMedCrossRef
102.
Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008, 117: 244-279.PubMedCrossRef
103.
Wei Y, Liu F, Li B, Chen X, Ma Y, Yan L, Wen T, Xu M, Wang W, Yang J: Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci. 2011, 56: 2227-2236.PubMedCrossRef
104.
Yang Y, Luo C, Feng R, Bi S: The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2011, 137: 947-952.PubMedCrossRef
105.
Guo YM, Yu WW, Shen XZ: Tumor necrosis factor rs361525 (−238G > A) polymorphism contributes to hepatocellular carcinoma susceptibility. Saudi Med J. 2010, 31: 1101-1105.PubMed
106.
Guo Y-M, Wei W-Y, Shen X-Z: Tumour necrosis factor 308 polymorphisms and hepatocellular carcinoma risk: a meta-analysis. Hepatogastroenterology. 2010, 57: 926-31.PubMed
107.
Skibola CF, Bracci PM, Nieters A, Brooks-Wilson A, De-Sanjosé S, Hughes AM, Cerhan JR, Skibola DR, Purdue M, Kane E, Lan Q, Foretova L, Schenk M, Spinelli JJ, Slager SL, De-Roos AJ, Smith MT, Roman E, Cozen W, Boffetta P, Kricker A, Zheng T, Lightfoot T, Cocco P, Benavente Y, Zhang Y, Hartge P, Linet MS, Becker N, Brennan P: Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol. 2010, 171: 267-276.PubMedCentralPubMedCrossRef
108.
Fang F, Yao L, Yu XJ, Yu L, Wu Q, Yu L: TNFalpha −308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10, 184 cases and 12, 911 controls. Breast Cancer Res Treat. 2010, 122: 267-271.PubMedCrossRef
109.
Zhang J, Dou C, Song Y, Ji C, Gu S, Xie Y, Mao Y: Polymorphisms of tumor necrosis factor-alpha are associated with increased susceptibility to gastric cancer: a meta-analysis. J Hum Genet. 2008, 53: 479-489.PubMedCrossRef
110.
Taylor PC: Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol. 2010, 10: 308-315.PubMedCrossRef
111.
Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR: TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol. 2008, 126: 13-30.PubMedCentralPubMedCrossRef
112.
Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F: The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology. 1999, 117: 1433-1437.PubMedCrossRef
113.
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002, 46: 3151-3158.PubMedCrossRef
114.
Alcaín G, Andrade RJ, Queipo de Llano MP, Moreno MJ, García-Cortés M, Franquelo E: Acute leukemia after infliximab therapy. Am J Gastroenterol. 2003, 98: 2577-PubMedCrossRef
115.
Bakland G, Nossent H: Acute myelogenous leukaemia following etanercept therapy. Rheumatology (Oxford). 2003, 42: 900-901. 10.1093/rheumatology/keg128.CrossRef
116.
Wolfe F, Michaud K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18, 572 patients. Arthritis Rheum. 2004, 50: 1740-1751.PubMedCrossRef
117.
Wolfe F, Michaud K: Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007, 56: 2886-2895.PubMedCrossRef
118.
Wolfe F, Michaud K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89, 710 person-years of observation. Arthritis Rheum. 2007, 56: 1433-1439.PubMedCrossRef
119.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006, 295: 2275-2285.PubMedCrossRef
120.
Peyrin-Biroulet L, Deltenre P, De-Suray N, Branche J, Sandborn WJ, Colombel J-F: Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008, 6: 644-653.PubMedCrossRef
121.
Leombruno JP, Einarson TR, Keystone EC: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009, 68: 1136-1145.PubMedCrossRef
122.
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ: Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009, 68: 1177-1183.PubMedCrossRef
123.
Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009, 7: 874-881.PubMedCentralPubMedCrossRef
124.
Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, Van-Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P: Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011, 70: 1895-1904.PubMedCrossRef
125.
Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM: The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011, 64: 1035-1050.PubMedCentralPubMedCrossRef
126.
Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D: Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011, 20: 119-130.PubMedCrossRef
127.
Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJK: Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011, 50: 552-562. 10.1093/rheumatology/keq343.CrossRef
128.
Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fulton S, Suarez-Almazor ME: Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012, 308: 898-908.PubMedCrossRef
129.
Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc J-L, Lapeyre-Mestre M: Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses. PLoS One. 2012, 7: e48991-PubMedCentralPubMedCrossRef
130.
Askling J, Van-Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L: Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum. 2009, 60: 3180-3189.PubMedCrossRef
131.
Singh JA, Noorbaloochi S, Singh G: Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010, CD008341-10.1002/14651858.CD008341.
132.
Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, Heresbach D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P: Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010, 69: 400-408.PubMedCentralPubMedCrossRef
133.
Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED: T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013, 108: 99-105.PubMedCrossRef
134.
Dunn LK, Feldman SR: Alefacept treatment for chronic plaque psoriasis. Skin Therapy Lett. 2010, 15: 1-3.PubMed
135.
Goffe B, Papp K, Gratton D, Krueger GG, Darif M, Lee S, Bozic C, Sweetser MT, Ticho B: An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther. 2005, 27: 1912-1921.PubMedCrossRef
136.
Bagust A, Boland A, Hockenhull J, Fleeman N, Greenhalgh J, Dundar Y, Proudlove C, Kennedy T, Moots R, Williamson P, Dickson R: Rituximab for the treatment of rheumatoid arthritis. Health Technol Assess. 2009, 13 (Suppl 2): 23-29.CrossRef
137.
Slimani S, Lukas C, Combe B, Morel J: Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine. 2011, 78: 484-487.PubMedCrossRef
138.
Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di-Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A: Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011, 29: 814-824.PubMedCrossRef
139.
140.
Simon TA, Smitten AL, Franklin J, Askling J, Lacaille D, Wolfe F, Hochberg MC, Qi K, Suissa S: Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis. 2009, 68: 1819-1826.PubMedCentralPubMedCrossRef
141.
Genovese MC, Schiff M, Luggen M, Le-Bars M, Aranda R, Elegbe A, Dougados M: Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol. 2012, 39: 1546-1554.PubMedCrossRef
142.
Gandhi M, Alwawi E, Gordon KB: Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg. 2010, 29: 48-52.PubMedCrossRef
143.
Reich K, Papp KA, Griffiths CEM, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu M-C, Lebwohl M, Gordon KB: An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012, 11: 300-312.PubMed
144.
Kary S, Burmester GR: Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int J Clin Pract. 2003, 57: 231-234.PubMed
145.
Strangfeld A, Hierse F, Rau R, Burmester G-R, Krummel-Lorenz B, Demary W, Listing J, Zink A: Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010, 12: R5-PubMedCentralPubMedCrossRef
146.
147.
Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DPM: Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2010, 62: 755-763. 10.1002/acr.20129.CrossRef
Metadata
Title
Cancer risk in immune-mediated inflammatory diseases (IMID)
Authors
Rudi Beyaert
Laurent Beaugerie
Gert Van Assche
Lieve Brochez
Jean-Christophe Renauld
Manuelle Viguier
Veronique Cocquyt
Guy Jerusalem
Jean-Pascal Machiels
Hans Prenen
Pierre Masson
Edouard Louis
Filip De Keyser
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-98

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification

Research

Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers

Review

The complexity of NF-κB signaling in inflammation and cancer

Research

Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis

Research

EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth

Research

Evaluation of p21 promoter for interleukin 12 radiation induced transcriptional targeting in a mouse tumor model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits